AfoliOpen Afoli →

Cladribine

Cladribine is an active ingredient of the class «Purine analogue».

Open in Afoli Medicines →

Pharmaceutical drug

Informational only — not medical advice. Ask a doctor or pharmacist; never change a dose on your own.

Boxed warning (US label)

Malignancies and risk of teratogenicity. Malignancies Treatment with MAVENCLAD may increase the risk of malignancy. MAVENCLAD is contraindicated in patients with current malignancy.

What it is used for

MAVENCLAD is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults.

US label

Litak is indicated for the treatment of hairy-cell leukaemia.

EMA

How it works

Class: Purine analogue

Common side effects

The following serious adverse reactions and potential risks are discussed, or discussed in greater detail, in other sections of the labeling: Malignancies Risk of Teratogenicity Lymphopenia Infections Hematologic Toxicity Graft-Versus-Host Disease With Blood Transfusion Liver Injury Hypersensitivity Cardiac Failure…

US label

Who should not take it

MAVENCLAD is contraindicated: in patients with current malignancy. in pregnant women and in females and males of reproductive potential who do not plan to use effective contraception during MAVENCLAD dosing and for 6 months after the last dose in each…

US label

Pregnancy and breastfeeding

MAVENCLAD is contraindicated in pregnant women and in females and males of reproductive potential who do not plan to use effective contraception.

Excerpts from the US prescribing label (public domain), copied without changes.

Interactions

Recorded interactions from open sources (Wikidata, US labels). The list is not complete — ask a pharmacist.

Brand names

United States

Leustatin · Mavenclad

European Union

Litak · Mavenclad

Canada

Apo-Cladribine · Auro-Cladribine · Mavenclad

Other trade names

Leustat

Approval status

US Food and Drug Administration
prescription · since 1993
European Medicines Agency
authorised · since 2004
Health Canada
prescription · marketed
First approval anywhere
1993

Codes

ATC
L01BB04, L04AA40
RxNorm CUI
44157
ChEMBL
CHEMBL1619
PubChem CID
20279
UNII
47M74X9YT5
Wikidata
Q414030

Frequently asked questions

What is Cladribine used for?

Cladribine is used for: Multiple sclerosis, Hairy cell leukemia, Lymphosarcoma, Chronic lymphocytic leukemia, Neoplasm, Immune disorder, and Anemia.

What kind of medicine is Cladribine?

Cladribine is an active ingredient of the class «Purine analogue».

What are the brand names of Cladribine?

Brand names of Cladribine include Leustatin, Mavenclad, Litak, Apo-Cladribine, Auro-Cladribine, and Leustat.

Medicines in the same class

Sources and licences

Updated November 15, 2026